TY - JOUR
T1 - Growth and nutritional status, and their association with lung function
T2 - A study from the international Primary Ciliary Dyskinesia Cohort
AU - Swiss PCD Group
AU - French Reference Centre for Rare Lung Diseases
AU - PCD Israeli Consortium
AU - Goutaki, Myrofora
AU - Halbeisen, Florian S.
AU - Spycher, Ben D.
AU - Maurer, Elisabeth
AU - Belle, Fabiën
AU - Amirav, Israel
AU - Behan, Laura
AU - Boon, Mieke
AU - Carr, Siobhan
AU - Casaulta, Carmen
AU - Clement, Annick
AU - Crowley, Suzanne
AU - Dell, Sharon
AU - Ferkol, Thomas
AU - Haarman, Eric G.
AU - Karadag, Bulent
AU - Knowles, Michael
AU - Koerner-Rettberg, Cordula
AU - Leigh, Margaret W.
AU - Loebinger, Michael R.
AU - Mazurek, Henryk
AU - Morgan, Lucy
AU - Nielsen, Kim G.
AU - Phillipsen, Maria
AU - Sagel, Scott D.
AU - Santamaria, Francesca
AU - Schwerk, Nicolaus
AU - Yiallouros, Panayiotis
AU - Lucas, Jane S.
AU - Kuehni, Claudia E.
N1 - Funding Information:
Support statement: The development of the international Primary Ciliary Dyskinesia (iPCD) Cohort is funded by the European Union’s Seventh Framework Programme (EG-GA No.35404 BESTCILIA: Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia). The primary ciliary dyskinesia (PCD) research at the Institute of Social and Preventive Medicine (ISPM) in Bern is supported by the Swiss National Science Foundation (SNF 320030_173044) and receives national funding from the Lung Leagues of Bern, St. Gallen, Vaud, Ticino and Valais, as well as the Milena-Carvajal Pro Kartagener Foundation. C. Kuehni is supported by the Swiss National Science Foundation (SNF32003B_162820 and SNF32003B_144068) while the national PCD service in Southampton and London is funded by the National Health Service (NHS) in England. The researchers participate in the Better Evidence to Advance Therapeutic Options for PCD (BEAT-PCD) network (COST action BM 1407). A Swiss National Science Foundation fellowship (PZ00P3_147987) supports B.D. Spycher. Swiss Cancer Research grants (KLS-3412-02-2014 and KLS-3644-02-2015) support F. Belle. The AAIR Charity (Reg. No. 1129698) supports L. Behan. S. Dell, T. Ferkol, M. Knowles, M.W. Leigh and S.D. Sagel are supported by the National Institutes of Health (U54HL096458). S.D. Sagel is also supported by local funding (CTSA NIH/NCATS Colorado UL1TR000154). Funding information for this article has been deposited with the Crossref Funder Registry.
Funding Information:
The development of the international Primary Ciliary Dyskinesia (iPCD) Cohort is funded by the European Union's Seventh Framework Programme (EG-GA No.35404 BESTCILIA: Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia). The primary ciliary dyskinesia (PCD) research at the Institute of Social and Preventive Medicine (ISPM) in Bern is supported by the Swiss National Science Foundation (SNF 320030_173044) and receives national funding from the Lung Leagues of Bern, St. Gallen, Vaud, Ticino and Valais, as well as the Milena-Carvajal Pro Kartagener Foundation. C. Kuehni is supported by the Swiss National Science Foundation (SNF32003B_162820 and SNF32003B_144068) while the national PCD service in Southampton and London is funded by the National Health Service (NHS) in England. The researchers participate in the Better Evidence to Advance Therapeutic Options for PCD (BEAT-PCD) network (COST action BM 1407). A Swiss National Science Foundation fellowship (PZ00P3_147987) supports B.D. Spycher. Swiss Cancer Research grants (KLS-3412-02-2014 and KLS-3644-02-2015) support F. Belle. The AAIR Charity (Reg. No. 1129698) supports L. Behan. S. Dell, T. Ferkol, M. Knowles, M.W. Leigh and S.D. Sagel are supported by the National Institutes of Health (U54HL096458). S.D. Sagel is also supported by local funding (CTSA NIH/NCATS Colorado UL1TR000154). Funding information for this article has been deposited with the Crossref Funder Registry. We want to thank all patients in the PCD cohort and their families, and we are grateful to the PCD patient organisations that closely collaborated with us. We thank all the researchers in the participating centres who helped collect and enter data, and worked closely with us throughout building the iPCD Cohort. We thank Zorica Zivkovic (Children's Hospital for Lung Diseases and TB, Medical Centre ?Dr Dragisa Misovic?, Belgrade, Serbia) for contributing patients from her centre. We appreciate the work of Edwige Collaud and Anna Bettina Meier (Institute of Social and Preventive Medicine, University of Bern, Switzerland) who helped us with the height and BMI z-score calculations for some countries. We also thank Kali Tal and Christopher Ritter (Institute of Social and Preventive Medicine, University of Bern, Switzerland) for their editorial suggestions.
Publisher Copyright:
Copyright © ERS 2017
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Chronic respiratory disease can affect growth and nutrition, which can influence lung function. We investigated height, body mass index (BMI), and lung function in patients with primary ciliary dyskinesia (PCD). In this study, based on the international PCD (iPCD) Cohort, we calculated z-scores for height and BMI using World Health Organization (WHO) and national growth references, and assessed associations with age, sex, country, diagnostic certainty, age at diagnosis, organ laterality and lung function in multilevel regression models that accounted for repeated measurements. We analysed 6402 measurements from 1609 iPCD Cohort patients. Height was reduced compared to WHO (z-score −0.12, 95% CI −0.17 to −0.06) and national references (z-score −0.27, 95% CI −0.33 to −0.21) in male and female patients in all age groups, with variation between countries. Height and BMI were higher in patients diagnosed earlier in life (p=0.026 and p<0.001, respectively) and closely associated with forced expiratory volume in 1 s and forced vital capacity z-scores (p<0.001). Our study indicates that both growth and nutrition are affected adversely in PCD patients from early life and are both strongly associated with lung function. If supported by longitudinal studies, these findings suggest that early diagnosis with multidisciplinary management and nutritional advice could improve growth and delay disease progression and lung function impairment in PCD.
AB - Chronic respiratory disease can affect growth and nutrition, which can influence lung function. We investigated height, body mass index (BMI), and lung function in patients with primary ciliary dyskinesia (PCD). In this study, based on the international PCD (iPCD) Cohort, we calculated z-scores for height and BMI using World Health Organization (WHO) and national growth references, and assessed associations with age, sex, country, diagnostic certainty, age at diagnosis, organ laterality and lung function in multilevel regression models that accounted for repeated measurements. We analysed 6402 measurements from 1609 iPCD Cohort patients. Height was reduced compared to WHO (z-score −0.12, 95% CI −0.17 to −0.06) and national references (z-score −0.27, 95% CI −0.33 to −0.21) in male and female patients in all age groups, with variation between countries. Height and BMI were higher in patients diagnosed earlier in life (p=0.026 and p<0.001, respectively) and closely associated with forced expiratory volume in 1 s and forced vital capacity z-scores (p<0.001). Our study indicates that both growth and nutrition are affected adversely in PCD patients from early life and are both strongly associated with lung function. If supported by longitudinal studies, these findings suggest that early diagnosis with multidisciplinary management and nutritional advice could improve growth and delay disease progression and lung function impairment in PCD.
UR - http://www.scopus.com/inward/record.url?scp=85042923509&partnerID=8YFLogxK
U2 - 10.1183/13993003.01659-2017
DO - 10.1183/13993003.01659-2017
M3 - Article
C2 - 29269581
AN - SCOPUS:85042923509
SN - 0903-1936
VL - 50
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 6
M1 - 1701659
ER -